In cancer, AKT is aberrantly activated throughPI3K-AKT pathwaystimulation by upstream receptor tyrosine kinases and/or PI3K/Rasmutations, and AKT gene amplification.−, ,  AKT mutations are less common but enhancethe oncogenesis of breast, uterine, colorectal, and prostate cancers., As such, AKT stands as an attractive drug target. The gene discussed is AKT1; the disease is prostate carcinoma.